Psychiatr. pro Praxi, 2007; 4: 165-167

Proč také pacienti nechtějí antipsychotika?

MUDr. Sylva Racková, MUDr. Luboš Janů Ph.D
Psychiatrická klinika FN a LF UK v Plzni

Schizophrenia is a serious disorder. There is necessary long-term antipsychotics´ medication in the treatment of schizophrenia. Compliance in the treatment is low. The presence of adverse events is one from the important reason of early discontinuation of antipsychotics, especially adverse events with unpleasant subjective experience. We would like to describe the importance of subjective reaction to antipsychotics – dysphoria and its importance in compliance and the course of this disorder.

Keywords: dysphoria, subjective experience, antipsychotics, D2 occupance, schizophrenia

Published: July 20, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Racková S, Janů L. Proč také pacienti nechtějí antipsychotika? Psychiatr. praxi. 2007;8(4):165-167.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Awad AG, Voruganti LNP. Neuroleptic dysphoria: revisiting the koncept 50 years later. Acta Psychiatr Scand 2005; 111 (Suppl. 427): 6-13. Go to original source... Go to PubMed...
    2. Cohen BM, Carlezon WA jr. Editorial can't get enough of that dopamine. Am J Psychiatry 2007; 164 (4): 543-546. Go to original source... Go to PubMed...
    3. Corrigan PW, Liberman RP, Engel JD. From noncompliance to collaboration in the treatment of schizophrenia. Hosp Community Psychiatry 1990; 41: 1203-1211. Go to original source... Go to PubMed...
    4. de Haan L, Lavalaye J, van Bruggen M, van Nimwegen L, Booij J, van Amelsvoort T, Linszen D. Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications. Can J Psychiatry 2004; 49: 290-296. Go to original source... Go to PubMed...
    5. de Haan L, Lavalaye J, Linszen D, Dingemans PM, Booij J. Subjective experience and striatal dopamine D (2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry 2000; 157: 1019-1020. Go to original source... Go to PubMed...
    6. de Haan L, van Bruggen M, Lavalaye J, Booij J, Dingemans PM, Linszen D. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry 2003; 160: 303-309. Go to original source... Go to PubMed...
    7. Gerlach J. Improving outcome in schizophrenia: The potential importance of EPS and neuroleptic dysphoria. Annals of Clinical Psychiatry. 2002; 14 (1): 47-57. Go to original source... Go to PubMed...
    8. Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: a reexamination comparing two measures. Psychol Med 1992, 22: 347-352. Go to original source... Go to PubMed...
    9. Hollister LE. Complications from the use of tranquilizing drugs. N Engl J Med 1957; 257: 170-177. Go to original source... Go to PubMed...
    10. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D2 occupancy, clinical response, and side effects: A double blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157: 514-520. Go to original source... Go to PubMed...
    11. Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology 2002; 162: 3-10. Go to original source... Go to PubMed...
    12. Marder SR. Subjective experiences on antipsychotic medications: synthesis and conclusions. Acta Psychiatr Scand 2005; 111 (Suppl. 427): 43-46. Go to original source... Go to PubMed...
    13. Mizrahi R, Rusjan P, Agid O, Graff A, Mamo DC, Zipursky RB, Kapur S. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. Am J Psychiatry 2007; 164: 630-637. Go to original source... Go to PubMed...
    14. Noordsy DL, Drake RE, Teague GB, Osher FC, Hurlbut SC, Beaudett MS, Paskus TS. Subjective experiences related to alcohol use among schizophrenics. J Nerv Ment Dis. 1991; 179 (7): 410-414. Go to original source... Go to PubMed...
    15. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241-247. Go to original source... Go to PubMed...
    16. Sarwer-Foner GJ, Kerenyi AB. Accumulated experience with transference and counter-transference aspect of the psychotropic drug, 1953-1960. In: Rothlin F, ed. Neuropsychopharmacology. Amsterdam: Elsevier, 1961: 385-361.
    17. Schimmelmann BG, Schacht M, Perro C, Lambert M. The initial dysphoric reaction to the first dose of neuroleptics. Nervenartzt January 2004; 75 (1): 36-43. Go to original source... Go to PubMed...
    18. Spanagel R, Weis F. The dopamine hypothesis of reward: past and current status. Trends Neurosci. 1999; 22: 521-527. Go to original source... Go to PubMed...
    19. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974; 31: 67-72. Go to original source... Go to PubMed...
    20. Van Puten T, May PRA. Subjective response as a predictor of outcome in pharmacotheraphy: the consumer has a point. Arch Gen Psychiatry 1978; 35: 477-480. Go to original source... Go to PubMed...
    21. Van Putten T, May PR, Marder SR. Response to antipsychotic medication: The doctor's and the consumer's view. Am J Psychiatry 1984; 141: 16-19. Go to original source... Go to PubMed...
    22. Voruganti LP, Awad AG. Brain imaging research on subjective response to psychotropic drugs. Acta Psychiatr Scand. 2005; 111 (Suppl. 427): 22-28. Go to original source... Go to PubMed...
    23. Voruganti LP, Awad AG. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berl) 2004; 171: 121-132. Go to original source... Go to PubMed...
    24. Weiden PJ, Mann JJ, Dixon L, Haas G, DeChillo N, Frances AJ. Is neuroleptic dysphoria a healthy response? Compr Psychiatry 1989; 30: 546-552. Go to original source... Go to PubMed...
    25. Wilk J, Marcus SC, West J, Countis L, Hall R, Regier DA, Olfson M. Substance abuse and the management of medication nonadherence in schizophrenia. J Nerv Ment Dis. 2006; 194 (6): 454-457. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.